logo

VYGR

Voyager Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.55 / 10
Netural

Voyager Therapeutics' fundamental assessment is fair (4.5/10). Strengths include an impressive 100% gross profit margin and positive PB-ROE, Asset-MV factors. However, low current and fixed assets turnover ratios introduce caution. The company's financial health is therefore balanced rather than robust, warranting monitoring of operational efficiency.

Fundamental(4.55)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-1.20
Score2/3
Weight15.98%
1M Return11.31%
Inventory turnover ratio
Value47.88
Score3/3
Weight7.21%
1M Return5.89%
Gross profit margin (%)
Value100.00
Score3/3
Weight15.95%
1M Return11.05%
Profit-MV
Value0.47
Score2/3
Weight11.01%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight11.16%
1M Return8.04%
PB-ROE
Value-0.15
Score2/3
Weight16.09%
1M Return11.23%
Current assets turnover ratio
Value0.10
Score0/3
Weight-2.56%
1M Return-2.30%
Fixed assets turnover ratio
Value0.55
Score1/3
Weight-1.46%
1M Return-1.34%
Asset-MV
Value-0.51
Score2/3
Weight15.69%
1M Return9.85%
Cash-MV
Value-0.07
Score2/3
Weight10.91%
1M Return7.78%
Is VYGR undervalued or overvalued?
  • VYGR scores 4.55/10 on fundamentals and holds a Fair valuation at present. Backed by its -35.53% ROE, -404.85% net margin, -1.90 P/E ratio, 0.93 P/B ratio, and -410.00% earnings growth, these metrics solidify its Netural investment rating.